Edition:
India

Immunomedics Inc (IMMU.OQ)

IMMU.OQ on NASDAQ Stock Exchange Global Market

12.44USD
8 Dec 2017
Change (% chg)

$0.58 (+4.89%)
Prev Close
$11.86
Open
$11.86
Day's High
$12.73
Day's Low
$11.39
Volume
1,253,382
Avg. Vol
778,610
52-wk High
$14.47
52-wk Low
$3.30

Select another date:

Fri, Nov 10 2017

BRIEF-Immunomedics appoints Michael Pehl president and CEO

* Immunomedics appoints Michael Pehl president and chief executive officer to lead next phase of transformative growth

BRIEF-Immunomedics announces first quarter fiscal results

* Immunomedics announces first quarter fiscal 2018 results and provides corporate update

BRIEF-Immunomedics to exchange about $80 mln of its 4.75 pct Convertible Senior Notes due 2020 for common stock

* Immunomedics announces agreements to exchange approximately $80.0 mln of its 4.75 pct Convertible Senior Notes due 2020 for common stock

BRIEF-Immunomedics presents interim phase 2 results with sacituzumab govitecan (i

* Immunomedics presents interim phase 2 results with sacituzumab govitecan (immu-132) in patients with pretreated metastatic urothelial cancer Source text for Eikon: Further company coverage:

BRIEF-Immunomedics announces publication of cancer drug data

* Immunomedics announces publication of phase 2 results with labetuzumab govitecan (immu-130) that demonstrate promising efficacy as a single agent in patients with metastatic colorectal cancer

BRIEF-Immunomedics reports Q4 loss per share $0.48

* Immunomedics announces fiscal 2017 results and strategic developments; reiterates guidance on bla submission timeline

BRIEF-Immunomedics files for offering of 34.8 mln shares of common stock by selling stockholders

* Immunomedics files for offering of 34.8 million shares of common stock by selling stockholders - sec filing

BRIEF-Immunomedics files for 34.8 mln shares of co's common stock

* Files for 34.8 million shares of co's common stock by the selling stockholders - sec filing

BRIEF-Seattle Genetics reports 8.2 percent stake in Immunomedics as of June 29, 2017

* Seattle genetics inc reports a 8.2 percent stake in immunomedics inc as of June 29, 2017 - sec filing

Select another date: